Filing Flows › Longeveron (LGVN) › Q1 2026
Longeveron (LGVN) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Longeveron (LGVN) reported revenue of $398K for the first quarter 2026 (Q1 2026), +4% from a year earlier and +9% from the quarter before.
Longeveron, Q1 2026: revenue $398K (+4% year over year), net loss $4.7M, operating cash flow −$4.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $398K | +9% | +4% |
| Operating profit | −$4.8M | — | — |
| Net earnings | −$4.7M | — | — |
| Operating cash flow | −$4.4M | — | — |
What changed
Revenue was $398K in Q1 2026, up 4% year over year and up 9% from the previous quarter. Clinical Trial Revenue was the largest line at 95% of revenue. Clinical Trial Revenue added $119K year over year (up 46%), 700% of the total change. Contract Manufacturing Revenue declined 83%.
Gross margin was 66.3%, down 5.8 points from Q1 2025. Operating costs exceeded revenue by $4.8M, an operating margin of -1199.7%. Operating expenses fell 8% while revenue rose 4%. The quarter ended with a net loss of $4.7M, narrower than the previous quarter's $5.4M loss.
Operating cash flow was −$4.4M. Non-cash charges added back $252K of depreciation and amortization and $379K of share-based compensation. Working capital and other items used $265K.
Questions
What was Longeveron's revenue in the first quarter 2026?
Longeveron (LGVN) reported revenue of $398K for the first quarter 2026 (Q1 2026), +4% from a year earlier and +9% from the quarter before.
Source: Longeveron 10-Q on SEC EDGAR.